Bevacizumab Regulates Cancer Cell Migration by Activation of STAT3
Huan-Huan Wu1, Shuai Zhang, Huan Bian
1Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China E-mail : kqwangyx@sina.com; guodazuo@sina.com.
Abstract:
There are numerous clinical cases indicating that long-term use of bevacizumab may increase the invasiveness of tumors. However, to date, little is known about underlying molecular mechanisms. Therefore, the purpose of our study was to investigate effects of bevacizumab in four cancer cells lines (WSU-HN6, CAL27, Tca83, and HeLa). It was found to promote migration and invasion in the WSU-HN6 and Tca83 cases, while exerting inhibitory effects in CAL27 and HeLa cells. The signal transducer and activator of transcription (STAT) 3 inhibitors niclosamide and S3I-201 inhibited the STAT3 signal pathway, which is activated by bevacizumab. These inhibitors also substantially blocked bevacizumab-induced migration of WSU-HN6 and Tca83 cells. Bevacizumab upregulated interleukin (IL)-6 and phosphorylated (p)-STAT3 expression time-dependently. Therefore, we propose that bevacizumab has differential effects on the migration of different cancer cell lines and promotes migration via the IL-6/STAT3 signaling pathway.
Insights
Bevacizumab differentially affects cancer cell migration, promoting it in some lines via the interleukin-6/signal transducer and activator of transcription 3 (IL-6/STAT3) pathway. Inhibitors blocked this bevacizumab-induced migration, revealing a key molecular mechanism.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Clinical observations suggest long-term bevacizumab use may enhance tumor invasiveness.
- The molecular mechanisms underlying bevacizumab's effects on tumor cell behavior remain largely unelucidated.
Purpose of the Study:
- To investigate the effects of bevacizumab on cancer cell migration and invasion.
- To explore the role of the signal transducer and activator of transcription (STAT) 3 pathway in bevacizumab's action.
- To identify potential molecular targets for modulating bevacizumab's effects.
Main Methods:
- Exposure of four cancer cell lines (WSU-HN6, CAL27, Tca83, HeLa) to bevacizumab.
- Assessment of cell migration and invasion.
- Treatment with STAT3 inhibitors (niclosamide, S3I-201).
- Analysis of interleukin-6 (IL-6) and phosphorylated (p)-STAT3 expression.
Main Results:
- Bevacizumab promoted migration and invasion in WSU-HN6 and Tca83 cells.
- Bevacizumab inhibited migration and invasion in CAL27 and HeLa cells.
- STAT3 inhibitors blocked bevacizumab-induced migration in WSU-HN6 and Tca83 cells.
- Bevacizumab upregulated IL-6 and p-STAT3 expression in a time-dependent manner.
Conclusions:
- Bevacizumab exhibits differential effects on the migration of various cancer cell lines.
- Bevacizumab-induced cancer cell migration is mediated through the IL-6/STAT3 signaling pathway.
- Targeting the IL-6/STAT3 pathway may offer a strategy to counteract bevacizumab-induced tumor cell migration.
Related Concept Videos
Cancer Cell Migration through Invadopodia
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
Cell Migration
Cell Migration
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Intracellular Signaling Affects Focal Adhesions
Some...


